(1) The combination analysis showed a significant improvement in DFS and no improvement in OS after 5 years of ovarian suppression and treatment with the aromatase inhibitor exemestane compared to 5 years of ovarian suppression and tamoxifen treatment after a median time of 5.7 years of follow-up. Recommendation: choose ovarian suppression + exemestane. (2) In young women with hormone receptor-positive early-stage breast cancer, 5 years of adjuvant tamoxifen application significantly reduces recurrence and improves survival. Several studies have evaluated ovarian suppression therapy alone or in combination with hormone therapy in early-stage hormone receptor-positive breast cancer, showing improved outcomes equivalent to or better than conventional chemotherapy regimens. Recommendation: when used alone, endocrine therapy is preferred. (3) Clinical improvement in the distant recurrence-free interval was seen in 57.4% of patients receiving chemotherapy with an absolute improvement rate of 2.6% in the TEXT trial and 3.4% in the SOFT trial for emeclizine. RECOMMENDATION: Five years of ovarian suppression combined with exemestane therapy in premenopausal patients with high-risk breast cancer receiving chemotherapy is a new treatment option that may reduce the risk of distant recurrence.